These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 28096333)

  • 1. Biophysical properties of the clinical-stage antibody landscape.
    Jain T; Sun T; Durand S; Hall A; Houston NR; Nett JH; Sharkey B; Bobrowicz B; Caffry I; Yu Y; Cao Y; Lynaugh H; Brown M; Baruah H; Gray LT; Krauland EM; Xu Y; Vásquez M; Wittrup KD
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):944-949. PubMed ID: 28096333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.
    Bailly M; Mieczkowski C; Juan V; Metwally E; Tomazela D; Baker J; Uchida M; Kofman E; Raoufi F; Motlagh S; Yu Y; Park J; Raghava S; Welsh J; Rauscher M; Raghunathan G; Hsieh M; Chen YL; Nguyen HT; Nguyen N; Cipriano D; Fayadat-Dilman L
    MAbs; 2020; 12(1):1743053. PubMed ID: 32249670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancing Therapeutic Protein Discovery and Development through Comprehensive Computational and Biophysical Characterization.
    Gentiluomo L; Svilenov HL; Augustijn D; El Bialy I; Greco ML; Kulakova A; Indrakumar S; Mahapatra S; Morales MM; Pohl C; Roche A; Tosstorff A; Curtis R; Derrick JP; Nørgaard A; Khan TA; Peters GHJ; Pluen A; Rinnan Å; Streicher WW; van der Walle CF; Uddin S; Winter G; Roessner D; Harris P; Frieß W
    Mol Pharm; 2020 Feb; 17(2):426-440. PubMed ID: 31790599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties.
    Svilenov HL; Arosio P; Menzen T; Tessier P; Sormanni P
    MAbs; 2023; 15(1):2164459. PubMed ID: 36629855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.
    Khetan R; Curtis R; Deane CM; Hadsund JT; Kar U; Krawczyk K; Kuroda D; Robinson SA; Sormanni P; Tsumoto K; Warwicker J; Martin ACR
    MAbs; 2022; 14(1):2020082. PubMed ID: 35104168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in silico assessment of the developability of a designed monoclonal antibody library.
    Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N
    MAbs; 2019; 11(2):388-400. PubMed ID: 30523762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deamidation and isomerization liability analysis of 131 clinical-stage antibodies.
    Lu X; Nobrega RP; Lynaugh H; Jain T; Barlow K; Boland T; Sivasubramanian A; Vásquez M; Xu Y
    MAbs; 2019 Jan; 11(1):45-57. PubMed ID: 30526254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five computational developability guidelines for therapeutic antibody profiling.
    Raybould MIJ; Marks C; Krawczyk K; Taddese B; Nowak J; Lewis AP; Bujotzek A; Shi J; Deane CM
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4025-4030. PubMed ID: 30765520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developability assessment during the selection of novel therapeutic antibodies.
    Jarasch A; Koll H; Regula JT; Bader M; Papadimitriou A; Kettenberger H
    J Pharm Sci; 2015 Jun; 104(6):1885-1898. PubMed ID: 25821140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing developability early in the discovery process for novel biologics.
    Fernández-Quintero ML; Ljungars A; Waibl F; Greiff V; Andersen JT; Gjølberg TT; Jenkins TP; Voldborg BG; Grav LM; Kumar S; Georges G; Kettenberger H; Liedl KR; Tessier PM; McCafferty J; Laustsen AH
    MAbs; 2023; 15(1):2171248. PubMed ID: 36823021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods.
    Wolf Pérez AM; Lorenzen N; Vendruscolo M; Sormanni P
    Methods Mol Biol; 2022; 2313():57-113. PubMed ID: 34478132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure, heterogeneity and developability assessment of therapeutic antibodies.
    Xu Y; Wang D; Mason B; Rossomando T; Li N; Liu D; Cheung JK; Xu W; Raghava S; Katiyar A; Nowak C; Xiang T; Dong DD; Sun J; Beck A; Liu H
    MAbs; 2019; 11(2):239-264. PubMed ID: 30543482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries.
    Dyson MR; Masters E; Pazeraitis D; Perera RL; Syrjanen JL; Surade S; Thorsteinson N; Parthiban K; Jones PC; Sattar M; Wozniak-Knopp G; Rueker F; Leah R; McCafferty J
    MAbs; 2020; 12(1):1829335. PubMed ID: 33103593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies.
    Yang X; Xu W; Dukleska S; Benchaar S; Mengisen S; Antochshuk V; Cheung J; Mann L; Babadjanova Z; Rowand J; Gunawan R; McCampbell A; Beaumont M; Meininger D; Richardson D; Ambrogelly A
    MAbs; 2013; 5(5):787-94. PubMed ID: 23883920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developability assessment for monoclonal antibody drug candidates: a case study.
    Garripelli VK; Wu Z; Gupta S
    Pharm Dev Technol; 2021 Jan; 26(1):11-20. PubMed ID: 32986499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highland games: A benchmarking exercise in predicting biophysical and drug properties of monoclonal antibodies from amino acid sequences.
    Coffman J; Marques B; Orozco R; Aswath M; Mohammad H; Zimmermann E; Khouri J; Griesbach J; Izadi S; Williams A; Sankar K; Walters B; Lin J; Hepbildikler S; Schiel J; Welsh J; Ferreira G; Delmar J; Mody N; Afdahl C; Cui T; Khalaf R; Hanke A; Pampel L; Parimal S; Hong X; Patil U; Pollard J; Insaidoo F; Robinson J; Chandra D; Blanco M; Panchal J; Soundararajan S; Roush D; Tugcu N; Cramer S; Haynes C; Willson RC
    Biotechnol Bioeng; 2020 Jul; 117(7):2100-2115. PubMed ID: 32255523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of next-generation therapeutic IgG4 with improved manufacturability and bioanalytical characteristics.
    Chen Z; Qian Y; Song Y; Xu X; Tao L; Mussa N; Ghose S; Li ZJ
    MAbs; 2020; 12(1):1829338. PubMed ID: 33044887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection.
    Lavoisier A; Schlaeppi JM
    MAbs; 2015; 7(1):77-83. PubMed ID: 25514497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space.
    Meanwell NA
    Chem Res Toxicol; 2016 Apr; 29(4):564-616. PubMed ID: 26974882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational optimization of a monoclonal antibody for simultaneous improvements in its solution properties and biological activity.
    Kumar S; Roffi K; Tomar DS; Cirelli D; Luksha N; Meyer D; Mitchell J; Allen MJ; Li L
    Protein Eng Des Sel; 2018 Jul; 31(7-8):313-325. PubMed ID: 30189027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.